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Abstract
Background: The Clinical Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines are the most popular breakpoint guidelines used in antimicrobial susceptibility
testing worldwide. The EUCAST guidelines are freely available to users while CLSI is available for non-members as a
package of three documents for US $500 annually. This is prohibitive for clinical microbiology laboratories in resource
poor settings. We set out to compare antibiotic susceptibility determined by the two guidelines to determine
whether adoption of EUCAST guidelines would significantly affect our susceptibility patterns.
Methods: We reviewed minimum inhibitory concentrations (MIC) of various antibiotics routinely reported for
Escherichia coli (E. coli), Staphylococcus aureus (S. aureus) and Pseudomonas aeruginosa (P. aeruginosa) isolates from
an automated microbiology identification system (VITEK-2) at the Aga Khan University Hospital Nairobi’s Pathology
department. These MICs were then analyzed using both CLSI 2015 and EUCAST 2015 guidelines and classified as
resistant, intermediate or susceptible. We compared the susceptibility and agreement between the CLSI and EUCAST
categorizations.
Results: Susceptibility data from a total of 5165 E. coli, 1103 S. aureus and 532 P. aeruginosa isolates were included.
The concordance rates of the two guidelines for E. coli, S. aureus and P. aeruginosa ranged from 78.2 to 100 %, 94.6 to
100 % and 89.1 to 95.5 % respectively. The kappa statistics for E. coli MICs revealed perfect agreement between CLSI
and EUCAST for cefotaxime, ceftriaxone and trimethoprim–sulfamethoxazole, almost perfect agreement for ampicillin,
ciprofloxacin, cefuroxime, gentamicin and ceftazidime, substantial agreement for meropenem, moderate agreement
for cefepime and amoxicillin-clavulanate, fair agreement for nitrofurantoin and poor agreement for amikacin. For S.
aureus the kappa statistics revealed perfect agreement for penicillin, trimethoprim–sulfamethoxazole, levofloxacin,
oxacillin, linezolid and vancomycin, almost perfect agreement for clindamycin, erythromycin and tetracycline and
moderate agreement for gentamicin. For P. aeruginosa the kappa analysis revealed moderate to almost perfect agreement for all the anti-pseudomonal antibiotics.
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Conclusion: The results show comparable antibiotic susceptibility patterns between CLSI and EUCAST breakpoints.
Given that EUCAST guidelines are freely available, it makes it easier for laboratories in resource poor settings to have
an updated and readily available reference for interpreting antibiotic susceptibilities.
Keywords: European Committee on Antimicrobial Susceptibility Testing (EUCAST), Clinical Laboratory Standards
Institute (CLSI), Antimicrobial susceptibility testing (AST), Minimum inhibitory concentrations (MIC)

Background
Over the last two decades, there has been emergence and
spread of antibiotic resistance in many bacterial clinical
pathogens [1]. Categorization of minimum inhibitory
concentrations (MIC) of various antibiotics in antimicrobial susceptibility testing (AST) depends on breakpoints
set by various international agencies. These breakpoints
affect clinical decision making by determining whether
an antibiotic is reported as susceptible or not. One of
the most popular guidelines used worldwide is from
the Clinical and Laboratory Standards Institute (CLSI)
whose interpretive cut offs for antibiotics is based on
MIC distributions, pharmacokinetic–pharmacodynamic
(PK-PD) properties and the mechanisms of resistance
[1]. The adoption of antibiotic susceptibility guidelines in
the US is regulated by the Food and Drug Administration
(FDA). In 1997 various national agencies in Europe came
together to form the European Committee on Antimicrobial Susceptibility Testing (EUCAST) that has since harmonized antibiotic interpretive breakpoints throughout
Europe and most European countries have since switched
from CLSI and their local guidelines to EUCAST guidelines [2, 3]. EUCAST bases its clinical breakpoints on
epidemiological MIC cut-offs (ECOFFS) and PK-PD
properties. All documents on MIC distributions and
ECOFFS are freely available on the EUCAST website [4].
Polsfuss et al. compared EUCAST with CLSI in screening for extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae isolates. They found no
significant difference in the sensitivity of the two guidelines in the detection of ESBL-producing isolates [5]. A
more recent study by Hombach et al. demonstrated significant differences in the susceptibility rates for drugs
including cefepime, ceftazidime and cefotaxime in the
detection of ESBLs between the CLSI 2013 and EUCAST
2013 AST guidelines. This study recommended adjustments to the clinical breakpoints to further harmonize
the two guidelines [6]. Since then 2014 and 2015 guidelines for both systems have been released in an effort to
harmonize the clinical breakpoints [7, 8].
CLSI guidelines have a number of disadvantages.
First, it is based on annual subscriptions of US $350 for
members and a cost of US $500 to non-members annually and this may be a problem for microbiology laboratories in resource poor settings. Secondly, details on the

decision making process are not accessible to the public.
Thirdly, the FDA has a major influence in determining
official clinical breakpoints before they are adopted by
CLSI and this raises major concerns on the influence of
pharmaceutical industries in establishing the guidelines.
CLSI has a voting committee comprising representatives of both the profession and the industry and hence
the industry plays a role in the decision making process.
As for EUCAST, the industry only plays a consultative
role and is not allowed to finance or participate in decision making [3]. EUCAST encourages the formation of
National Antimicrobial Susceptibility Testing Committees (NAC) that can send a representative to sit in its
General Committee (GC) thus fostering inclusivity in the
decision making process [3]. Finally, antibiotics that are
not registered in the US may not be included in the CLSI
guidelines.
For resource poor settings like Africa, there is need for
guidelines that are accessible and affordable while still
maintaining quality of reported susceptibility. Given that
antibiotic susceptibility is quite variable across different
settings, we set out to compare the susceptibility rates of
selected antibiotics based on CLSI 2015 and EUCAST
2015 AST guidelines and the level of agreement between
the two guidelines.

Methods
The study was carried out at the Aga Khan University
Hospital, Nairobi’s (AKUHN) Department of Pathology.
Ethical exemption was granted by the AKUHN’s research
and ethics committee (Ref 2015/REC-44) since this type
of study is low risk and classified as a clinical audit. This
was a retrospective study reviewing the MICs of various
antimicrobials on one commonly isolated gram positive organism, Staphylococcus aureus (S. aureus), one
fermenting gram negative organism, Escherichia coli (E.
coli) and one non-fermenting gram negative organism,
Pseudomonas aeruginosa (P. aeruginosa). MIC data for
E. coli, P. aeruginosa and S. aureus isolates was collected
from two Vitek 2 (version 4.01, bioMerieux, Marcyl’Etoile, France) automated microbiology systems for the
period January 2012 to December 2014. The Vitek 2 ASTP580 and AST-GN26/AST-GN83 cards were used for
antibiotic susceptibility for S. aureus and E. coli/P. aeruginosa respectively. Ceftriaxone MICs were only available

Kassim et al. Ann Clin Microbiol Antimicrob (2016) 15:21

Page 3 of 7

for the year 2014 in the AST-GN83 cards for a total of
1673 E. coli isolates. The data was summarized using
Microsoft Excel 2013 and imported into IBM (International Business Machines, Corporation; Armonk, New
York, United States of America) SPSS (Statistical Package for the Social Sciences) Version 22.0 that was used
for analysis. The MICs were then analyzed using both
the CLSI 2015 and EUCAST 2015 guidelines to categorize them as either susceptible, intermediate or resistant
[7, 8]. The concordance rate between the two guidelines
in percentage was compared. The susceptibility rates for
the various antimicrobial agents were also calculated in
percentages for each organism. Analysis of the extent of
agreement between CLSI 2015 and EUCAST 2015 for
the various antimicrobials was carried out using Cohen’s
kappa statistics and graded from perfect agreement to
poor agreement [9]. Cohen’s Kappa statistics determines
the proportion of agreement over and above chance
between two independent observations. This ranges from
−1 to 1 and a p value less than 0.05 means that the agreement reported is significantly different from 0 and is not
due to chance. For all inferential statistics, a p value less
than 0.05 was considered statistically significant.

Results
A total of 5165 E. coli, 1103 S. aureus and 532 P. aeruginosa non-duplicate isolates were included in the analysis.
Of the 5165 E. coli MICs analyzed, there was comparable susceptibility to most antibiotics including ampicillin,
amoxicillin–clavulanate, cefuroxime, cefotaxime, ceftriaxone, trimethoprim–sulfamethoxazole, ciprofloxacin,

gentamicin and meropenem between the two guidelines.
The concordance between the two guidelines ranged
from 78.2 to 100 %. Table 1 summarizes the susceptibilities, concordance and kappa statistics between the two
guidelines for E. coli.
The E. coli susceptibility patterns achieved after analysis using EUCAST 2015 and CLSI 2015 guidelines are
similar except for amoxicillin–clavulanate, amikacin and
nitrofurantoin. Analysis year by year did not show any
difference in the trends and overall susceptibilities. The
kappa analysis revealed perfect agreement for ceftriaxone, cefotaxime and trimethoprim–sulfamethoxazole
with kappa (κ) of 1 (p < 0.000). An almost perfect agreement was noted with ampicillin κ = 0.985 (95 % CI 0.979,
0.991), p < 0.000, ciprofloxacin κ = 0.969 (95 % CI 0.963,
0.975), p < 0.000, cefuroxime κ = 0.924 (95 % CI 0.914,
0.934), p < 0.000, ceftazidime κ = 0.859 (95 % CI 0.843,
0.85), p < 0.000 and gentamicin κ = 0.979 (95 % CI 0.973,
0.985), p < 0.000. Substantial agreement was noted with
meropenem κ = 0.724 (95 % CI 0.573, 0.875), p < 0.000
while moderate agreement was noted with amoxicillinclavulanate κ = 0.581 (95 % CI 0.567, 0.595), p < 0.000
and cefepime κ = 0.600 (95 % CI 0.578, 0.622), p < 0.000.
Fair agreement was seen with nitrofurantoin κ = 0.351
(95 % CI 0.314, 0.388), p < 0.000 while poor agreement
was noted with amikacin κ = 0.112 (95 % CI 0.079,
0.145), p < 0.000.
Of the 1103 S. aureus MICs analyzed, susceptibility
to penicillin, oxacillin, levofloxacin, linezolid, trimethoprim–sulfamethoxazole,
vancomycin,
clindamycin,
erythromycin and tetracycline was comparable between

Table 1 Susceptibilities of E. coli to various antibiotics, concordance and kappa statistics between CLSI 2015 and EUCAST
2015 guidelines
Antibiotic

CLSI (%); n = 5165
S

I

EUCAST (%); n = 5165
R

S

I

R

Concordance (%)

Kappa, κ (95 % CI)

Ampicillin

13.8

0.5

85.7

13.8

0

86.2

99.5

0.985 (0.979, 0.991)

Amox-Clav

55.8

23.8

20.4

55.8

0

44.2

78.2

0.581 (0.567, 0.595)

TMP/SMX

0

0

100

0

0

100

100

1

Nitrofurantoin

84.6

11.9

3.5

96.5

0

3.5

87.6

0.351 (0.314, 0.388)

Ciprofloxacin

57.3

0.2

42.5

55.9

1.4

42.7

98.4

0.969 (0.963, 0.975)

Cefuroxime

63.7

3.5

32.8

63.7

0

36.3

96.5

0.924 (0.914, 0.934)

Gentamicin

78.5

0.2

21.3

78.1

0.4

21.5

99.5

0.979 (0.973, 0.985)

Amikacin

99.3

0.3

0.4

90.5

8.8

0.7

91.1

0.112 (0.079, 0.145)

Cefotaxime

69.7

0.4

29.9

69.7

0.4

29.9

100

1

Ceftazidime

76.3

0.9

22.8

71.5

4.8

23.7

93.7

0.859 (0.843, 0.85)

Ceftriaxone

67.7

0.1

32.2

67.7

0.1

32.2

100

1

Cefepime

80.5

10.0

9.5

72.9

9.8

17.3

84.9

0.600 (0.578, 0.622)

Meropenem

99.7

0.1

0.2

99.8

0.1

0.1

99.7

0.724 (0.573, 0.875)

Amox-Clav amoxicillin–clavulanate, TMP/SMX trimethoprim–sulfamethoxazole, S susceptible, I intermediate, R resistant
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ceftazidime, ciprofloxacin, cefepime, gentamicin, meropenem and piperacillin–tazobactum. The susceptibilities, concordance and kappa statistics between the two
guidelines are shown in Table 3. Year by year analysis did
not show any differences in trends and susceptibility patterns. The kappa analysis for CLSI 2015 and EUCAST
2015 guidelines revealed moderate to almost perfect
agreement for all the anti-pseudomonal antibiotics. P
values for the kappa statistics for all the antibiotics were
statistically significant at p < 0.000. Overall, the antibiotic
susceptibility patterns were quite similar regardless of
whether CLSI or EUCAST 2015 guidelines were used.

the two guidelines. The susceptibilities, concordance and
kappa statistics between the two guidelines are shown in
Table 2.
For S. aureus the susceptibilities are generally very
similar between the two guidelines. Year by year analysis did not show any differences in trends and susceptibility patterns. The kappa analysis for CLSI 2015 and
EUCAST 2015 guidelines revealed perfect agreement for
levofloxacin, linezolid, vancomycin, oxacillin, penicillin
and trimethoprim–sulfamethoxazole with a kappa statistic of 1 (p < 0.000). An almost perfect agreement was
noted with clindamycin κ = 0.904 (95 % CI 0.826, 0.982),
p < 0.000, erythromycin κ = 0.978 (95 % CI 0.960, 0.996),
p < 0.000 and tetracycline κ = 0.962 (95 % CI 0.940,
0.984), p < 0.000. Moderate agreement was noted with
gentamicin κ = 0.537 (95 % CI 0.441, 0.633), p < 0.000.
For the 532 P. aeruginosa analyzed there were similar
susceptibility patterns noted between CLSI 2015 and
EUCAST 2015. Antibiotics analyzed included amikacin,

Discussion
The morbidity and mortality associated with communicable diseases including bacterial infections is quite significant in developing countries [10]. Antibiotics play a
critical role in treating such infections especially when
instituted in a timely fashion more so when the bacteria

Table 2 Susceptibilities of S.aureus to various antibiotics and the concordance and kappa statistics between CLSI 2015
and EUCAST 2015 guidelines
Antibiotic

CLSI (%); n = 1103

EUCAST (%); n = 1103

Concordance (%)

Kappa, κ (95 % CI)

S

I

R

S

I

R

Penicillin

10.6

0

89.4

10.6

0

89.4

100

1

TMP/SMX

0

0

100

0

0

100

100

1

Clindamycin

98.0

0.3

1.7

98.0

0.1

1.9

99.5

0.904 (0.826, 0.982)

Erythromycin

85.6

0.5

13.9

86.0

0

14.0

99.4

0.978 (0.960, 0.996)

Gentamicin

96.3

0.5

3.2

91.5

0

8.5

94.6

0.537 (0.441, 0.633)

Levofloxacin

90.8

0.3

8.9

90.8

0.3

8.9

100

1

Linezolid

100

0

0

100

0

0

100

1

Oxacillin

93.3

0

6.7

93.3

0

6.7

100

1

Tetracycline

83.2

0.1

16.7

82.4

0.8

16.8

98.9

0.962 (0.940, 0.984)

Vancomycin

100

0

0

100

0

0

100

1

TMP/SMX trimethoprim–sulfamethoxazole, S susceptible, I intermediate, R resistant

Table 3 Susceptibilities of P.aeruginosa to various antibiotics and the concordance and kappa statistics between CLSI
2015 and EUCAST 2015 guidelines
CLSI (%); n = 532
S

I

EUCAST (%); n = 532
R

S

I

Concordance (%)

Kappa, κ (95 % CI)

R

Amikacin

79.5

3.0

17.5

72.2

7.3

20.5

89.7

0.734 (0.703; 0.765)

Ceftazidime

70.9

4.7

24.4

70.9

0

29.1

95.3

0.890 (0.870; 0.910)

Cefepime

72.6

4.7

22.7

72.6

0

27.4

95.3

0.886 (0.866; 0.906)

Gentamicin

72.6

6.2

21.2

72.6

0

27.4

93.8

0.851 (0.829; 0.873)

Meropenem

64.1

8.3

27.6

64.1

12.8

23.1

95.5

0.912 (0.895; 0.929)

Pip-taz

64.5

8.3

27.3

64.5

0

35.5

91.7

0.830 (0.808; 0.852)

Ciprofloxacin

71.8

5.3

22.9

66.2

5.6

28.2

89.1

0.762 (0.736; 0.788)

Pip-Taz piperacillin–tazobactum, CI confidence interval, S susceptible, I intermediate, R resistant
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is susceptible to the antibiotic given. The determination of accurate antibiotic susceptibility is therefore an
important cog in the clinical care of bacterial infections
especially in organisms that possess acquired resistance
mechanisms and careful consideration should be given
when deciding how to interpret phenotypic susceptibility data [11]. In Kenya, many laboratories have adopted
CLSI guidelines as a basis for interpreting their susceptibility data despite the fact that it costs between US
$300–$500. These guidelines are updated annually and
therefore require laboratories to keep on purchasing
them at a cost that is prohibitive to most public laboratories. Failure to stay updated may result in misinterpretation of susceptibility. For example in 2013, CLSI
abandoned the use of oxacillin disc diffusion in determining whether a S. aureus isolate is methicillin resistant in
favour of cefoxitin because it was more accurate in determining the presence of a mecA mediated mechanism of
resistance [12]. In 2012, it adopted a new disc diffusion
susceptibility cut off for ciprofloxacin of 31 mm up from
21 mm for non-typhoidal Salmonella (NTS) isolated
from invasive specimens and all Salmonella Typhi isolated from both invasive and non-invasive specimens.
The MIC for the same was reduced from 1 to 0.06 μg/mL
resulting in many Salmonella spp. previously reported
as susceptible to fall into the intermediate category, and
many that were intermediate were now categorized as
resistant [13]. In 2013, CLSI recommended that these cut
offs should apply to all Salmonella spp. including NTS
from non-invasive specimens [12, 14]. In the same year
new levofloxacin and ofloxacin breakpoints were introduced for Salmonella spp. including Salmonella Typhi.
These changes were motivated by an increased risk of
treatment failure in patients with decreased ciprofloxacin susceptible Salmonella spp [15]. In 2012 again, CLSI
reduced meropenem and piperacillin-tazobactum MIC
breakpoints for P. aeruginosa from ≤4 to ≤2 ug/mL
and ≤64 ug/mL to ≤16 ug/mL respectively [13]. These
examples highlight the importance of remaining up-todate and emphasizes the need for an affordable, up-todate and readily available guideline for the interpretation
of antibiotic susceptibility.
In our comparison of CLSI and EUCAST guidelines
for interpretation of antibiotic susceptibility, for E. coli,
most of the antibiotics had moderate to perfect agreement between the two guidelines with kappa values
ranging from 0.581 to 1 and two-thirds of them having
almost perfect or perfect agreement with kappa values
ranging from 0.859 to 1. Poor agreement was noted with
amikacin with EUCAST having a more stringent breakpoint for susceptibility of ≤8 mg/L compared to the CLSI
breakpoint of ≤16 mg/L. The major discrepancy was
in the intermediate and susceptible categories as 8.8 %
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of isolates labeled as intermediate by EUCAST were all
categorized as susceptible by CLSI. EUCAST guidelines
eliminated the intermediate category for some antibiotics and this explains the reduced level of agreement for
some of the antibiotics. For example, CLSI categorized
23.8 % of E. coli as having intermediate susceptibility to
amoxicillin-clavulanate but were all categorized as resistant by EUCAST while 11.9 % categorized as intermediate
susceptibility to nitrofurantoin by CLSI were categorized
as susceptible by EUCAST. From a clinical stand point,
reclassifying amoxicillin-clavulanate from intermediate to resistant is unlikely to adversely affect the patient
as it simply removes it from being a therapeutic consideration. As for nitrofurantoin, its ability to concentrate
in urine enables it to achieve significant concentrations
and eliminate isolates that may have intermediate susceptibility. Therefore, the reclassification of isolates that
are intermediate by CLSI to susceptible by EUCAST is
unlikely to contribute to adverse outcomes for patients
with urinary tract infections. The EUCAST guidelines
have slightly more stringent breakpoints for some antibiotics in an effort to curb the inappropriate use of antibiotics and control the rising rates of antibiotic resistance.
For S. aureus, all except one of the antibiotics had moderate to perfect agreement and three quarters of them
had almost perfect or perfect agreement with kappa
values ranging from 0.862 to 1. The two guidelines performed equally in the detection of the rate of methicillin
resistant Staphylococcus aureus (MRSA) of 7.2 %. Vancomycin susceptible Staphylococcus aureus (VSSA) were
also detected equally by the two guidelines. EUCAST
eliminated the intermediate category for vancomycin
in a bid to discourage the reporting of Glycopeptideintermediate Staphylococcus aureus (GISA) due to poor
response even to increased doses of vancomycin [8, 16].
In view of the fact that no vancomycin resistant Staphylococcus aureus (VRSA) has been identified in our set up
as yet, these changes are unlikely to influence interpretation of breakpoints. The moderate level of agreement
for gentamicin is due to the more stringent breakpoints
by EUCAST leading to a much higher resistance rate of
8.6 % compared to 3.2 % by CLSI. The difference between
the two susceptibility cut-offs is two dilutions and this
may require further harmonization. Gentamicin is rarely
used as monotherapy in treating gram positive bacteria
and as such this difference in MIC cut off is unlikely to be
clinically significant.
For P. aeruginosa, five out of seven of the antibiotics
had almost perfect agreement with kappa values ranging
from 0.830 to 0.912 with the remaining two having moderate agreement with kappa values of 0.762 and 0.734.
EUCAST abolished the intermediate category for ceftazidime, cefepime, gentamicin and piperacillin-tazobactum
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reclassifying the MICs as resistant. This accounts for
the slightly reduced level of agreement. For amikacin
and ciprofloxacin, with moderate agreement, EUCAST
has more stringent breakpoints for susceptibility of ≤8
and ≤0.5 ug/mL compared to CLSI breakpoints of ≤16
and ≤1 ug/mL respectively. These accounted for the
reduced level of agreement and may require further
harmonization between the two breakpoints. For meropenem, EUCAST uses a resistant breakpoint of >8 ug/
mL while CLSI uses ≥8 ug/mL. In effect this has led to
a slightly higher meropenem resistance of 27.6 % compared to 23.1 % for CLSI and EUCAST respectively. This
is another aspect that will require harmonization.
Our study is limited by the fact that we only compared
the susceptibility for three bacteria whose results may not
necessarily be generalizable to all clinically relevant gram
positive and negative bacteria. However, these three bacteria represent a significant proportion of common bacterial pathogens both in the community and healthcare
settings namely Enterobacteriaceae, non-fermenting
gram negative bacteria and Staphylococci. The results
obtained are also limited to MICs generated by an automated bacterial identification system which is not widely
used in developing countries. For P. aeruginosa, Colistin had not yet been included in the gram negative AST
cards being used at the time the study was being conducted. Colistin Etest® (bioMerieux, Durham, NC, USA)
was only run for multi-drug resistant isolates of clinical
significance but this data was not available for analysis.
In most laboratories in sub-Saharan Africa, disk diffusion
is the preferred mode of antibiotic susceptibility testing.
However, disk diffusion cut offs generally approximate
MIC cut offs fairly well and we think a similar comparison based on disc diffusion cut offs would yield similar
results.

Conclusion
Our study shows acceptable level of agreement between
EUCAST and CLSI 2015 AST guidelines for E. coli, S.
aureus and P. aeruginosa and laboratories with similar
antibiotic susceptibility patterns may choose to adopt
either guideline without fear of significantly altering
reported antibiotic susceptibility. With EUCAST guidelines being freely available it should be considered as
an alternative especially in resource poor settings in
order to maintain up-to-date antibiotic susceptibility
interpretation.
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